Home
Diseases
Gastric Cancer

Gastric Cancer

Disease

Also known as: GC

Disease Profile

Gastric cancer, also known as stomach cancer, is a malignant tumor arising from the lining of the stomach. Most cases are gastric carcinomas, though other histologies can occur. Disease often presents late because early symptoms are nonspecific, contributing to poor outcomes in advanced-stage diagnosis.

Category: Gastrointestinal malignancy
Prevalence: In 2022, approximately 968,350 cases were reported globally

ICD Codes

Related News

CT-Based Biomarker Improves Gastric Cancer Prognosis; PET Imaging Market Grows; Neuroendocrine Tumor Research Advances

Jun 24, 2026

Brazilian researchers developed a CT-based biomarker called VMD that combines visceral fat and muscle radiodensity to predict gastric cancer prognosis, with patient survival ranging from 13.8 to 58.5 months. The global PET imaging market is projected to grow to $1.4 billion by 2032 as cancer cases rise globally. Neuroendocrine tumor research is advancing with new funding and studies on Hedgehog signaling pathways.

Multiple Oncology Trials Report Positive Results at ASCO 2026 and in Journals

Jun 02, 2026

Multiple oncology trials present recent results, including cabozantinib-nivolumab activity in non-clear cell RCC, savolitinib efficacy in MET-amplified gastric cancer, and induction nivolumab feasibility in HPV-driven oropharyngeal cancer.

Compugen Reports Q1 2026 Financial Results, Provides Pipeline Update

Jun 02, 2026

Compugen reported a Q1 2026 net loss of $7.7 million with approximately $134.9 million in cash, expecting runway into 2029. The COM701 MAIA-ovarian trial is enrolling across the U.S., Israel, and France, with interim analysis expected by Q1 2027. Partner AstraZeneca is advancing rilvegostomig across 11 Phase 3 trials.

BioNTech, BioLineRx Unveil Clinical Data at ASCO 2026

May 31, 2026

BioNTech presented phase 2 data for HER2-directed ADC Trastuzumab Pamirtecan showing 47.9% response rate in endometrial cancer, with FDA submission planned for 2026. BioLineRx dosed first patient in phase 1/2a GLIX1 trial for glioblastoma and reported new preclinical data. Both companies presented at ASCO 2026.

ABL111 gains FDA accelerated approval pathway as phase 2 gastric cancer trial begins

May 13, 2026

ABL111 received FDA agreement on an accelerated approval pathway for metastatic gastric cancer as the first patient was dosed in a global phase 2 trial. The companies said ORR will support accelerated approval and phase 2 is evaluating ABL111 with nivolumab and mFOLFOX6.

Immunotherapy, Targeted Therapy, and mRNA Vaccines Reshaping Cancer Care

May 07, 2026

Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.

Single-Cell Study Reveals Resistance Mechanisms to Trastuzumab Deruxtecan in HER2-Positive Gastric Cancer

Apr 29, 2026

Single-cell RNA sequencing of nearly 92,000 cells from the DESTINY-Gastric06 trial reveals distinct primary and acquired resistance mechanisms to trastuzumab deruxtecan in HER2-positive gastric cancer, including MUC3A and CST3 as key drivers.

Compass Therapeutics Reports Mixed Biliary Tract Cancer Data, Plans FDA Meeting for Tovecimig BLA

Apr 28, 2026

Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.

AstraZeneca nears pivotal data readout for sonesitatug vedotin in Claudin18.2 gastric cancer

Apr 24, 2026

AstraZeneca will report pivotal first-half data on sonesitatug vedotin in Claudin18.2 gastric cancer. The phase 3 Clarity-Gastric01 study is enrolling patients with ≥25% expression.

Claudin 18.2 Immunotherapy Pipeline Centers on Next-Generation Candidates After Zolbetuximab

Apr 21, 2026

VYLOY (zolbetuximab-clzb) remains the only approved CLDN18.2-targeted therapy for first-line HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors. The pipeline is focused on next-generation antibodies, ADCs, CAR-T, NK-cell and bispecific approaches aiming to build on zolbetuximab benchmark data.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07595523	Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency	NOT_YET_RECRUITING	PHASE2
NCT07587229	Alternative Splicing Based Prediction of Chemotherapy Response in Gastric Cancer	RECRUITING
NCT07581405	GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer	NOT_YET_RECRUITING	PHASE2
NCT07565818	Spectral CT Combined With MSI for Predicting Regional Lymph Node Metastasis in Gastric Cancer	ACTIVE_NOT_RECRUITING	NA
NCT07561073	Comparison of Partial Stomach-Partitioning and Conventional Gastrojejunostomy for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer	RECRUITING	NA
NCT07554742	Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging	NOT_YET_RECRUITING
NCT07542262	Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers	ENROLLING_BY_INVITATION	PHASE2
NCT07537361	Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer	RECRUITING	PHASE2
NCT07529808	Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07528131	18F-FDG PET/CT in Gastric Cancer	COMPLETED